You are here

Aminoglycosides with reduced ototoxicity

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI126874-01
Agency Tracking Number: R41AI126874
Amount: $600,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA15-270
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-01
Award End Date (Contract End Date): 2019-07-31
Small Business Information
Greenville, SC 29605-4255
United States
DUNS: 831389122
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (864) 656-1106
Business Contact
Phone: (864) 656-1106
Research Institution
CLEMSON, SC 29634-0001
United States

 Nonprofit college or university

Aminoglycosides are one of the cheapest and well known antibiotics in clinical
use for over years but one of the major limitations in their use is their ototoxicity We
are developing fast and low cost methods to develop aminoglycosides with anti
ribosomal activities and reduced toxicity In this project we will identify novel
aminoglycoside antibacterials that show reduced ototoxicity Complexes between
ribosomal components will be exploited as targets for small molecule drug libraries that
inactivate the ribosome stopping bacterial protein synthesis and causing bacterial death
while reducing toxicity This work addresses an important health issue antibiotic
ototoxicity and presents creative steps towards a novel solution to this problem
The work proposed here a multidisciplinary effort encompassing antibacterial
screening and ototoxicity studies using zebrafish and guinea pig models describes the
development of novel aminosugar rRNA binders as non toxic antibacterial therapeutics
The success of the proposed work would be a significant addition to currently available
approaches in antibacterial therapy We propose using a zebrafish assay to identify
conjugates that show reduced toxicities opening possibilities for developing reduced
toxicity RNA targeted aminosugar therapeutics PROJECT NARRATIVE
The proposed project presents a strategy for developing novel aminoglycoside therapeutics with
reduced ototoxicities with evasion of resistance Antimicrobial resistance occurs when
microorganisms often infectious bacteria viruses and certain parasites are no longer sensitive
to drugs that were previously used to treat them this is of global concern because it hampers
our ability to control infectious disease and increases the costs of health care In order to
combat this world wide problem innovative strategies for antibiotic drug design must be
implemented The proposed research describes a strategy for improving the therapeutic index
of aminoglycosides by designing novel structures that lower their ototoxicity and evade common
resistance pathways

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government